Actively Recruiting
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Led by Xijing Hospital · Updated on 2026-01-23
18
Participants Needed
1
Research Sites
123 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.
CONDITIONS
Official Title
Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic coronary syndrome
- Non-target coronary lesions with stenosis of 50% or more by visual assessment
- Angina symptoms that can be managed with antianginal medication
- High attenuation coefficient (≥-70.1 HU) of perivascular adipose tissue around non-target lesions as seen on coronary CT angiography
- Ability to complete follow-up and comply with prescribed medication
You will not qualify if you...
- Younger than 18 years old
- Unable to give informed consent or currently participating in another trial without reaching its primary endpoint
- Pregnant or nursing women (pregnancy test required within 7 days prior for women of childbearing potential)
- Medical conditions with life expectancy less than 3 years
- Hemodynamically unstable patients
- Known allergies or contraindications to study drug, heparin, or contrast agents
- Abnormal laboratory tests at screening indicating liver, blood cell, or kidney impairment
- Severe systemic diseases, tumors, immune disorders, infections, or malignancies making study participation inappropriate according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ling Tao
Xi'an, Shannxi, China, 710032
Actively Recruiting
Research Team
C
Chao Gao, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here